Clinical activity of ipilimumab in acral melanoma: A retrospective review

Oncologist

Volumn 20, Issue 6, 2015, Pages 648-652

  Johnson, Douglas B ^a   Peng, Chengwei ^a   Abramson, Richard G ^a   Ye, Fei ^a   Zhao, Shilin ^a   Wolchok, Jedd D ^b   Sosman, Jeffrey A ^a   Carvajal, Richard D ^c   Ariyan, Charlotte E ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Department of Medicine   (United States)

Author keywords

Acral; CKIT; CTLA 4; Immune therapy; Ipilimumab; Melanoma

Indexed keywords

HYDROCORTISONE; IPILIMUMAB; LACTATE DEHYDROGENASE; LEVOTHYROXINE; MONOCLONAL ANTIBODY;

ACRAL MELANOMA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COLITIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HYPOPHYSITIS; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKIN TOXICITY; VERY ELDERLY; PATHOLOGY; REMISSION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MELANOMA; REMISSION INDUCTION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SKIN NEOPLASMS;

EID: 84932620801     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0468     Document Type: Article

References (31)

1. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
2. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526.
3. Prieto PA, Yang JC, Sherry RM et al. CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039-2047.
4. McDermott D, Haanen J, Chen TT et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 2013;24:2694-2698.
5. Luke JJ, Callahan MK, Postow MA et al. Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013;119:3687-3695.
6. Postow MA, Luke JJ, Bluth MJ et al. Ipilimumab for patients with advanced mucosal melanoma. The Oncologist 2013;18:726-732.
7. Maio M, Danielli R, Chiarion-Sileni V et al. Efficacy andsafetyof ipilimumabin patients with pre-treated, uveal melanoma. Ann Oncol 2013;24:2911-2915.
8. Del Vecchio M, Di Guardo L, Ascierto PA et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 2014;50:121-127.
9. Bradford PT, Goldstein AM, McMaster ML et al. Acral lentiginous melanoma: Incidence and survival patterns in the United States, 1986-2005. Arch Dermatol 2009;145:427-434.
10. 10. Wu XC, Eide MJ, King J et al. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006. J Am Acad Dermatol 2011;65(suppl 1):S26-S37.
11. Piliang MP. Acral lentiginous melanoma. Clin Lab Med 2011;31:281-288.
12. Bello DM, Chou JF, Panageas KS et al. Prognosis of acral melanoma: A series of 281 patients. Ann Surg Oncol 2013;20:3618-3625.
13. Chi Z, Li S, Sheng X et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases. BMC Cancer 2011;11:85.
14. Chang JW, Yeh KY, Wang CH et al. Malignant melanoma in Taiwan: A prognostic study of 181 cases. Melanoma Res 2004;14:537-541.
15. Luk NM, Ho LC, Choi CLetal. Clinicopatholog-ical features and prognostic factors of cutaneous melanoma among Hong Kong Chinese. Clin Exp Dermatol 2004;29:600-604.
16. Kuno Y, Ishihara K, Yamazaki N et al. Clinical and pathological features of cutaneous malignant melanoma: A retrospective analysis of 124 Japanese patients. Jpn J Clin Oncol 1996;26:144-151.
17. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147.
18. Lovly CM, Dahlman KB, Fohn LE et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012;7:e35309.
19. Hodis E, Watson IR, Kryukov GV et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-263.
20. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
21. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
22. Wolchok JD, Hoos A, O’Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
23. O’Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 2010;21:1712-1717.
24. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-5598.
25. Krauthammer M, Kong Y, Ha BH et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-1014.
26. Niu HT, Zhou QM, Wang Fetal. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. Pigment Cell Melanoma Res 2013;26:646-653.
27. Griewank KG, Murali R, Puig-Butille JA et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst 2014;106
28. Dai J, Kong Y, Si L et al. Large-scale analysis of pdgfra mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. Clin Cancer Res 2013;19:6935-6942.
29. Furney SJ, Turajlic S, Stamp G et al. The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res 2014;27:835-838.
30. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-2199.
31. Lee SJ, Lim HJ, Choi YH et al. The clinical significance of tumor-infiltrating lymphocytes and microscopic satellites in acral melanoma in a korean population. Annals Dermatol 2013;25:61-66.